company background image
RDG logo

Read-Gene WSE:RDG Stock Report

Last Price

zł5.18

Market Cap

zł61.1m

7D

9.3%

1Y

70.4%

Updated

24 Jul, 2024

Data

Company Financials

RDG Stock Overview

Engages in the detection, prevention, and treatment of various types of cancer.

RDG fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Read-Gene S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Read-Gene
Historical stock prices
Current Share Pricezł5.18
52 Week Highzł7.80
52 Week Lowzł2.80
Beta-1.2
11 Month Change8.37%
3 Month Change-6.50%
1 Year Change70.39%
33 Year Change91.85%
5 Year Change488.64%
Change since IPO91.85%

Recent News & Updates

Does Read-Gene (WSE:RDG) Have A Healthy Balance Sheet?

Jul 17
Does Read-Gene (WSE:RDG) Have A Healthy Balance Sheet?

Read-Gene (WSE:RDG) Is Making Moderate Use Of Debt

Feb 14
Read-Gene (WSE:RDG) Is Making Moderate Use Of Debt

Recent updates

Does Read-Gene (WSE:RDG) Have A Healthy Balance Sheet?

Jul 17
Does Read-Gene (WSE:RDG) Have A Healthy Balance Sheet?

Read-Gene (WSE:RDG) Is Making Moderate Use Of Debt

Feb 14
Read-Gene (WSE:RDG) Is Making Moderate Use Of Debt

Read-Gene S.A.'s (WSE:RDG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 17
Read-Gene S.A.'s (WSE:RDG) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Shareholder Returns

RDGPL BiotechsPL Market
7D9.3%2.7%-1.1%
1Y70.4%-12.3%10.6%

Return vs Industry: RDG exceeded the Polish Biotechs industry which returned -12.3% over the past year.

Return vs Market: RDG exceeded the Polish Market which returned 10.6% over the past year.

Price Volatility

Is RDG's price volatile compared to industry and market?
RDG volatility
RDG Average Weekly Movement5.3%
Biotechs Industry Average Movement5.3%
Market Average Movement5.1%
10% most volatile stocks in PL Market9.0%
10% least volatile stocks in PL Market3.2%

Stable Share Price: RDG has not had significant price volatility in the past 3 months.

Volatility Over Time: RDG's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200521Jan Lubinskiwww.read-gene.com

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. Chemoprevention is the use of natural or synthetic substances to stop, reverse, or delay the process of developing cancer.

Read-Gene S.A. Fundamentals Summary

How do Read-Gene's earnings and revenue compare to its market cap?
RDG fundamental statistics
Market capzł61.07m
Earnings (TTM)-zł1.94m
Revenue (TTM)zł10.66m

5.7x

P/S Ratio

-31.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RDG income statement (TTM)
Revenuezł10.66m
Cost of Revenuezł1.03m
Gross Profitzł9.63m
Other Expenseszł11.57m
Earnings-zł1.94m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 12, 2024

Earnings per share (EPS)-0.16
Gross Margin90.32%
Net Profit Margin-18.15%
Debt/Equity Ratio177.6%

How did RDG perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.